Ra Pharmaceuticals, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | |
|---|---|---|---|---|---|---|
| Revenue | $3.0M | $2.5M | — | $1.9M | $4.1M | $4.8M |
| Operating income | −$107.0M | −$66.4M | −$55.0M | −$28.0M | −$13.4M | −$7.1M |
| Net income | −$19.0M | −$16.5M | −$11.4M | −$28.9M | −$13.9M | −$5.5M |
| Total assets | $284.2M | $219.2M | $80.2M | $126.8M | $24.3M | — |
| Total liabilities | $22.0M | $12.1M | $11.0M | $9.6M | $7.9M | — |
| Equity | $262.1M | $207.1M | $69.2M | $117.2M | −$37.2M | −$25.7M |
| EPS (diluted) | — | — | — | — | — | — |
| Shares out. | 42.2M | 32.3M | 22.5M | 22.5M | 536,690 | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2019- Operating margin
- −3566.0%
- Net margin
- −634.6%
- Return on equity
- −7.3%
- Return on assets
- −6.7%
- Return on capital (ROCE)
- −40.3%
- Liabilities / assets
- 7.8%
- Debt / equity
- 0.08×
- Book value / share
- $6.21
- Revenue growth (YoY)
- 20.0%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2019- Altman Z″ (distress)
- 12.53safe
- Accruals / assets
- 24.0%high accruals
- Piotroski F-Score
- 1/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 4 warning● 3 good- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- High accruals — earnings-quality risk
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventApr 2, 2020
- Other material eventMar 31, 2020
- Entered a material agreementMar 16, 2020
- Other material eventFeb 28, 2020
- Shareholder vote · Other material eventDec 18, 2019
- Other material eventNov 25, 2019
- Entered a material agreement · Regulation FD disclosureOct 10, 2019
- Other material eventJul 26, 2019
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.